Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00346424 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters
A Phase 3 study, sponsored by ARCA Biopharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT00346424 is a Phase 3 study that has completed, run by ARCA Biopharma. The registered enrollment target is 300 participants.
The verdict
NCT00346424, a Phase 3 study, has completed, sponsored by ARCA Biopharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of the study is to compare the safety and effectiveness of alfimeprase to a placebo in restoring function of occluded central catheters.
Interventions
- DRUG Alfimeprase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2005-09 |
| Est. Completion | 2006-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00346424
The ClinicalTrials.gov registry entry for NCT00346424 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ARCA Biopharma, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Alfimeprase is the first listed.
NCT00346424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00346424 about?
NCT00346424 is a clinical study titled "Safety and Efficacy Study of Alfimeprase in Subjects With Occluded Central Catheters". The purpose of the study is to compare the safety and effectiveness of alfimeprase to a placebo in restoring function of occluded central catheters.
What is the current status of trial NCT00346424?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2005-09. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00346424?
The interventions under investigation include: Alfimeprase (DRUG).
Who is sponsoring clinical trial NCT00346424?
This trial is sponsored by ARCA Biopharma, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.